Theravance Biopharma (TBPH) EPS (Weighted Average and Diluted) Growth (1y) (2020 - 2026)
Theravance Biopharma (TBPH) EPS (Weighted Average and Diluted) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
251.11% |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
-13.31% |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
102.51% |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
-79.34% |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
- |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
-103.05% |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
61.45% |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
- |
| 10 |
Theravance Biopharma |
835.85 Mn |
441.18 Mn |
- |
62.96% |
| Date | Value |
|---|
| Mar 31, 2026 |
62.96% |
| Dec 31, 2025 |
470.97% |
| Sep 30, 2025 |
126.92% |
| Jun 30, 2025 |
417.65% |
| Mar 31, 2025 |
-12.50% |
| Dec 31, 2024 |
-82.35% |
| Sep 30, 2024 |
-52.94% |
| Jun 30, 2024 |
-21.43% |
| Mar 31, 2024 |
31.43% |
| Dec 31, 2023 |
19.05% |
| Sep 30, 2023 |
19.05% |
| Jun 30, 2023 |
-154.55% |
| Mar 31, 2023 |
36.36% |
| Dec 31, 2022 |
51.16% |
| Sep 30, 2022 |
56.25% |
| Jun 30, 2022 |
86.25% |
| Mar 31, 2022 |
59.26% |
| Dec 31, 2021 |
53.26% |
| Sep 30, 2021 |
58.62% |
| Jun 30, 2021 |
20.00% |
